Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [6][25] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [6][25] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [7][25] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [20][21] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [22] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery technologies and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][20] - The closures segment saw solid product volume growth, particularly in beverages [5][22] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][30] - There is an emphasis on productivity measures to mitigate higher production costs and improve margins [3][30] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [7][26] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued strong growth in the pharma segment, excluding emergency medicine, which is facing destocking challenges [32] - The company expects steady improvements in beauty margins and a return to growth in the closures segment [30][32] - The outlook for Q1 2026 includes adjusted earnings per share expected to be in the range of $1.13-$1.21 [29] Other Important Information - The company returned $486 million to shareholders through share repurchases and dividends in 2025 [7][26] - The company achieved a record quarter for tooling sales in Q4 2025, indicating strong customer retention [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [38][39] Question: What is the expectation for EBITDA margin trends throughout the year? - Management anticipates stronger margins in the second half of the year, driven by improvements in beauty and closures segments [40][41] Question: Can you provide specifics on the margin performance in beauty and closures? - Management noted operational issues in beauty due to environmental upgrades and maintenance in closures, with expectations for improvements in Q1 [50][51] Question: What is the outlook for emergency medicine sales? - Management expects a revenue headwind of approximately $65 million in 2026, primarily in the first half [28][66] Question: How should growth in Narcan and cough and cold products be expected to stabilize? - Management anticipates low to mid-single-digit growth for Narcan and expects to update on cough and cold product performance by Q2 [74][76]